Clinical Utility of ctDNA in the Treatment of Oligometastatic Disease

Starting soon

Conditions studied: Oligometastatic Cancer

In brief

This prospective observational study investigates the clinical utility of circulating tumor DNA (ctDNA) in patients with oligometastatic disease (OMD) undergoing definitive-intent local ablative treatment (LAT). The study aims to evaluate ctDNA as a prognostic and response biomarker before, during, and after LAT across cancer types and treatment modalities. Serial plasma samples and archival tumor tissue will be analyzed to assess ctDNA detection rates, elimination patterns, minimal residual disease, and association with recurrence, progression, and survival outcomes.

Key facts

Study ID

NCT07426250

Run by

Aarhus University Hospital

People needed

500

Starts

2026-03-01

Expected to finish

2030-09-01

Last updated by the study team

2026-02-23

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Metastatic spread from histopathological diagnosed solid cancer
• Planned for LAT (local ablative therapy) for OMD (oligometastatic disease)
• ≥ 18 years
• Written and oral consent

You may not qualify if…

• Other cancer disease within 5 years
• Conditions that will contraindicate blood samples

Where it is running

• Department of Oncology, Aarhus University Hospital — Aarhus N, Denmark

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.